You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 12, 2024

Lasmiditan succinate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for lasmiditan succinate and what is the scope of freedom to operate?

Lasmiditan succinate is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lasmiditan succinate has eighty-five patent family members in forty-three countries.

One supplier is listed for this compound.

Summary for lasmiditan succinate
International Patents:85
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 17
Patent Applications: 1
DailyMed Link:lasmiditan succinate at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for lasmiditan succinate
Generic Entry Date for lasmiditan succinate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for LASMIDITAN SUCCINATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
REYVOW Tablets lasmiditan succinate 50 mg and 100 mg 211280 1 2024-01-31

US Patents and Regulatory Information for lasmiditan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for lasmiditan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 ⤷  Try a Trial ⤷  Try a Trial
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for lasmiditan succinate

Country Patent Number Title Estimated Expiration
South Korea 20040094872 ⤷  Try a Trial
Norway 330394 ⤷  Try a Trial
China 115385893 与吡啶酰基哌啶5-HT1F激动剂相关的组合物和方法 (Compositions and methods related to picolinylpiperidine 5-HT1F agonists) ⤷  Try a Trial
Philippines 12019501252 COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HTIF AGONISTS ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.